Elocon: Advanced Topical Corticosteroid for Effective Dermatitis Control
Elocon
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $40.00 | $40.00 (0%) | 🛒 Add to cart |
| 2 | $30.00 | $80.00 $60.00 (25%) | 🛒 Add to cart |
| 3 | $26.67 | $120.00 $80.00 (33%) | 🛒 Add to cart |
| 4 | $25.00 | $160.00 $100.00 (38%) | 🛒 Add to cart |
| 5 | $24.00 | $200.00 $120.00 (40%) | 🛒 Add to cart |
| 6 | $23.33 | $240.00 $140.00 (42%) | 🛒 Add to cart |
| 7 | $22.86 | $280.00 $160.00 (43%) | 🛒 Add to cart |
| 8 | $21.25 | $320.00 $170.00 (47%) | 🛒 Add to cart |
| 9 | $20.00 | $360.00 $180.00 (50%) | 🛒 Add to cart |
| 10 | $19.00
Best per bottle | $400.00 $190.00 (52%) | 🛒 Add to cart |
Elocon (mometasone furoate) is a high-potency topical corticosteroid formulation designed for the targeted treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. As a class IV corticosteroid, it offers potent anti-inflammatory, antipruritic, and vasoconstrictive properties with an optimized safety profile when used appropriately. This monograph provides comprehensive information for healthcare professionals regarding the pharmacological characteristics, clinical applications, and appropriate usage parameters of this established dermatological therapeutic agent.
Features
- Contains mometasone furoate 0.1% as the active pharmaceutical ingredient
- Available in multiple formulations: cream, ointment, and lotion
- Enhanced epidermal penetration with minimal systemic absorption
- Vasoconstrictor assay demonstrates high potency relative to other topical corticosteroids
- Formulations are fragrance-free and non-comedogenic
- Stable chemical composition with demonstrated shelf life of 24 months
Benefits
- Rapid reduction of inflammation, erythema, and pruritus within 24-48 hours of application
- High efficacy in managing moderate to severe corticosteroid-responsive dermatoses
- Flexible formulation options allow for treatment customization based on lesion characteristics and body site
- Minimal systemic absorption reduces risk of HPA axis suppression compared to other high-potency corticosteroids
- Once-daily dosing regimen improves patient compliance and treatment adherence
- Cost-effective therapeutic option with proven long-term management capabilities
Common use
Elocon is primarily indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses including atopic dermatitis, psoriasis (excluding widespread plaque psoriasis), seborrheic dermatitis, and contact dermatitis. It is particularly effective in managing chronic lichenified lesions and intertriginous areas when used appropriately. The preparation demonstrates significant efficacy in reducing scaling, erythema, and induration associated with various dermatological conditions. Clinical studies have shown improvement in Physician Global Assessment scores within two weeks of initiation.
Dosage and direction
Apply a thin film of Elocon to the affected area once daily. The amount required depends on the severity and extent of the condition being treated. For most dermatoses, a 15-30 gram tube is sufficient for two weeks of treatment when applied to 15-20% of body surface area. The medication should be gently rubbed into the affected skin until no longer visible. Duration of treatment should be limited to 2 weeks for most indications, not exceeding 4 weeks in resistant cases. Occlusive dressings may be used for recalcitrant conditions but increase systemic absorption risk.
Precautions
Elocon should not be used in the presence of cutaneous infections unless appropriate antimicrobial therapy is concurrently administered. Avoid application to the face, groin, and axillae unless specifically directed by a healthcare provider. Discontinue treatment if irritation develops. Patients should be advised not to use tight-fitting diapers or plastic pants on children being treated in the diaper area. Use with caution in patients with liver impairment. Periodic evaluation of HPA axis function may be necessary during prolonged therapy.
Contraindications
Hypersensitivity to mometasone furoate or any component of the formulation. Contraindicated in patients with viral skin infections (herpes simplex, varicella), fungal infections, and tuberculous skin lesions. Not recommended for use in rosacea, perioral dermatitis, or acne vulgaris. Should not be applied to ulcerated areas or open wounds. Avoid use in children under 2 years of age.
Possible side effect
The most common adverse reactions include burning sensation (2-3%), pruritus (1-2%), and skin atrophy (1%) with prolonged use. Less frequently reported effects include folliculitis, hypertrichosis, hypopigmentation, and contact dermatitis. Systemic absorption may lead to reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Striae may occur with prolonged use, particularly in intertriginous areas and under occlusive dressings.
Drug interaction
No formal drug interaction studies have been conducted with topical corticosteroids. However, patients receiving concomitant therapy with other corticosteroids (oral, parenteral, or topical) may experience enhanced systemic effects. Caution should be exercised when using with other potentially hepatotoxic drugs. The effect on P450 enzyme systems is considered minimal due to low systemic absorption.
Missed dose
If a dose is missed, apply as soon as remembered unless it is almost time for the next application. Do not apply double the amount to make up for a missed dose. Resume the regular dosing schedule. Consistent application is important for therapeutic efficacy, but occasional missed doses are unlikely to significantly impact treatment outcomes.
Overdose
Topically applied Elocon can be absorbed in sufficient amounts to produce systemic effects. Acute overdose is unlikely but may manifest as systemic corticosteroid effects including hypercorticism and adrenal suppression. In case of chronic overdose, treatment should be discontinued gradually. Supportive measures should be instituted as necessary. There is no specific antidote for mometasone furoate overdose.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F). Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Do not freeze. Keep out of reach of children. Discard any unused product after the treatment period has ended.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card.
Reviews
Clinical studies demonstrate Elocon’s efficacy with 78% of patients showing significant improvement in atopic dermatitis symptoms within two weeks. Dermatologists consistently rate it as a first-line choice for moderate inflammatory dermatoses due to its favorable efficacy-to-safety ratio. Patient satisfaction surveys indicate high compliance rates attributed to once-daily dosing and rapid symptom relief. Long-term studies show maintained efficacy with proper treatment cycling and appropriate follow-up care.